A panelist discusses how topical JAK inhibitors and AhR agonists represent emerging therapeutic approaches for atopic dermatitis that target specific inflammatory pathways to provide effective symptom relief with distinct mechanisms of action.

A panelist discusses how topical PDE4 inhibitors provide an effective, non-steroidal treatment option for atopic dermatitis by reducing inflammation and improving symptoms with a favorable safety profile.

A panelist discusses how clinicians can select optimal topical treatments for atopic dermatitis by carefully weighing efficacy against potential side effects to create personalized management plans for patients.

A panelist discusses how primary care practitioners can implement efficient diagnostic protocols and treatment pathways to better manage atopic dermatitis patients within the constraints of busy clinical settings.

A panelist discusses how healthcare providers can effectively identify and manage atopic dermatitis flares across different age groups, highlighting the unique challenges and treatment approaches for both pediatric and adult populations.

Your daily dose of the clinical news you may have missed.

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Awareness of the psychological burden of eczema is improving, LeBovidge says, but if clinicians don't address mental health, patients and families will suffer in silence.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Family physician and researcher Mark Ebell, MD, discusses the clinical implications, efficacy, and role of gepotidacin in UTI management.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

Your daily dose of the clinical news you may have missed.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

The Women’s Sexual Health Test (Visby Medical) delivers results in approximately 30 minutes using a vaginal swab.

Lepodisiran at 400 mg maintained reductions of Lp(a), an inherited risk factor for cardiovascular disease, at ~90% at 1 year and ~75% at 1.5 years, Eli Lilly reported.

Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.

Your daily dose of the clinical news you may have missed.

New research shows that treating both men and women with topical and oral antibiotics lowers the odds of bacterial vaginosis recurrence by more than half.

The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.

The model identified BMI, tobacco use, and family history of CRC as the strongest predictors for advanced neoplasia in young adults.

In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.

Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.

Panelists discuss how there is no change in therapeutic indication based on this particular finding, though it may serve as a beneficial side effect for patients struggling with sleep difficulties.

Panelists discuss how long-term safety data for fezolinetant and elinzanetant remain unavailable, though short-term results show very positive outcomes with significantly higher efficacy than previous treatment options.